PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
3.02 - 3.02
2.85 - 3.74
400 / 3.8K (Avg.)
12.58 | 0.24
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
18.02%
Revenue growth above 1.5x IXX.DE's 1.35%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
15.57%
Gross profit growth at 50-75% of IXX.DE's 23.32%. Martin Whitman would question if cost structure or brand is lagging.
251.12%
EBIT growth above 1.5x IXX.DE's 35.02%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
251.12%
Operating income growth above 1.5x IXX.DE's 13.23%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
24.37%
Net income growth above 1.5x IXX.DE's 12.08%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
20.00%
EPS growth of 20.00% while IXX.DE is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
20.00%
Diluted EPS growth of 20.00% while IXX.DE is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
7.82%
Share count expansion well above IXX.DE's 0.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.82%
Diluted share count expanding well above IXX.DE's 0.00%. Michael Burry would fear significant dilution to existing owners' stakes.
-100.00%
Dividend reduction while IXX.DE stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-52.88%
Negative OCF growth while IXX.DE is at 183.88%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-74.16%
Negative FCF growth while IXX.DE is at 311.92%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
64.62%
10Y revenue/share CAGR at 50-75% of IXX.DE's 108.71%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
64.62%
5Y revenue/share CAGR 1.25-1.5x IXX.DE's 49.28%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
29.67%
3Y revenue/share CAGR similar to IXX.DE's 27.10%. Walter Schloss would assume both companies experience comparable short-term cycles.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
226.96%
Positive 10Y CAGR while IXX.DE is negative. John Neff might see a substantial advantage in bottom-line trajectory.
226.96%
Positive 5Y CAGR while IXX.DE is negative. John Neff might view this as a strong mid-term relative advantage.
100.21%
Positive short-term CAGR while IXX.DE is negative. John Neff would see a clear advantage in near-term profit trajectory.
109.56%
Equity/share CAGR of 109.56% while IXX.DE is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
109.56%
5Y equity/share CAGR above 1.5x IXX.DE's 35.76%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
77.45%
3Y equity/share CAGR above 1.5x IXX.DE's 13.11%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39.31%
Our AR growth while IXX.DE is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
9.16%
Inventory growth well above IXX.DE's 6.66%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
6.04%
Asset growth above 1.5x IXX.DE's 1.38%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
1.22%
Positive BV/share change while IXX.DE is negative. John Neff sees a clear edge over a competitor losing equity.
-12.02%
We’re deleveraging while IXX.DE stands at 4.32%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
10.69%
SG&A growth well above IXX.DE's 0.31%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.